drugset
drugset / Trial / NCT07465224

A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

NCT07465224 ↗

Phase 2 Recruiting 40 enrolled Alnylam Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM

Timeline

Start
2026-01-15
Primary completion
2027-05-28
Completion
2027-05-28

Drugs

EvaluationDrugModalityDoseRoute
Subject ALN-4324 Unknown — Subcutaneous

Indications

type 2 diabetes mellitus